549 related articles for article (PubMed ID: 28972960)
1. Strategies to enhance paracrine potency of transplanted mesenchymal stem cells in intractable neonatal disorders.
Park WS; Ahn SY; Sung SI; Ahn JY; Chang YS
Pediatr Res; 2018 Jan; 83(1-2):214-222. PubMed ID: 28972960
[TBL] [Abstract][Full Text] [Related]
2. Mesenchymal stem cell therapy for intractable neonatal disorders.
Ahn SY; Park WS; Sung SI; Chang YS
Pediatr Neonatol; 2021 Feb; 62 Suppl 1():S16-S21. PubMed ID: 33485822
[TBL] [Abstract][Full Text] [Related]
3. Role of Stromal-Derived Factor-1 in Mesenchymal Stem Cell Paracrine-Mediated Tissue Repair.
Luo Q; Zhang B; Kuang D; Song G
Curr Stem Cell Res Ther; 2016; 11(7):585-92. PubMed ID: 27306402
[TBL] [Abstract][Full Text] [Related]
4. C-Kit Positive Cardiac Stem Cells and Bone Marrow-Derived Mesenchymal Stem Cells Synergistically Enhance Angiogenesis and Improve Cardiac Function After Myocardial Infarction in a Paracrine Manner.
Bao L; Meng Q; Li Y; Deng S; Yu Z; Liu Z; Zhang L; Fan H
J Card Fail; 2017 May; 23(5):403-415. PubMed ID: 28284757
[TBL] [Abstract][Full Text] [Related]
5. Pre-treatments enhance the therapeutic effects of mesenchymal stem cells in liver diseases.
Hu C; Wu Z; Li L
J Cell Mol Med; 2020 Jan; 24(1):40-49. PubMed ID: 31691463
[TBL] [Abstract][Full Text] [Related]
6. Stem cells for neonatal brain injury - Lessons from the bench.
Ahn SY; Chang YS; Park WS
Semin Perinatol; 2023 Apr; 47(3):151726. PubMed ID: 37003920
[TBL] [Abstract][Full Text] [Related]
7. Bcl-2 engineered MSCs inhibited apoptosis and improved heart function.
Li W; Ma N; Ong LL; Nesselmann C; Klopsch C; Ladilov Y; Furlani D; Piechaczek C; Moebius JM; Lützow K; Lendlein A; Stamm C; Li RK; Steinhoff G
Stem Cells; 2007 Aug; 25(8):2118-27. PubMed ID: 17478584
[TBL] [Abstract][Full Text] [Related]
8. Thrombin Preconditioning Enhances Therapeutic Efficacy of Human Wharton's Jelly-Derived Mesenchymal Stem Cells in Severe Neonatal Hypoxic Ischemic Encephalopathy.
Kim YE; Sung SI; Chang YS; Ahn SY; Sung DK; Park WS
Int J Mol Sci; 2019 May; 20(10):. PubMed ID: 31137455
[TBL] [Abstract][Full Text] [Related]
9. Mechanistic effects of mesenchymal and hematopoietic stem cells: New therapeutic targets in myocardial infarction.
Shafei AE; Ali MA; Ghanem HG; Shehata AI; Abdelgawad AA; Handal HR; ElSayed AS; Ashaal AE; Ali MM; El-Shal AS
J Cell Biochem; 2018 Jul; 119(7):5274-5286. PubMed ID: 29266431
[TBL] [Abstract][Full Text] [Related]
10. Substance P enhances the therapeutic effect of MSCs by modulating their angiogenic potential.
Hong HS; Kim S; Jin Y; Son Y
J Cell Mol Med; 2020 Nov; 24(21):12560-12571. PubMed ID: 32985796
[TBL] [Abstract][Full Text] [Related]
11. Effect of the Microenvironment on Mesenchymal Stem Cell Paracrine Signaling: Opportunities to Engineer the Therapeutic Effect.
Kusuma GD; Carthew J; Lim R; Frith JE
Stem Cells Dev; 2017 May; 26(9):617-631. PubMed ID: 28186467
[TBL] [Abstract][Full Text] [Related]
12. Preconditioning mesenchymal stem cells with transforming growth factor-alpha improves mesenchymal stem cell-mediated cardioprotection.
Herrmann JL; Wang Y; Abarbanell AM; Weil BR; Tan J; Meldrum DR
Shock; 2010 Jan; 33(1):24-30. PubMed ID: 19996917
[TBL] [Abstract][Full Text] [Related]
13. Human Amniotic Fluid Stem Cells: Therapeutic Potential for Perinatal Patients with Intractable Neurological Disease.
Ochiai D; Masuda H; Abe Y; Otani T; Fukutake M; Matsumoto T; Miyakoshi K; Tanaka M
Keio J Med; 2018 Dec; 67(4):57-66. PubMed ID: 29515049
[TBL] [Abstract][Full Text] [Related]
14. Hypoxic preconditioning improves the survival and pro-angiogenic capacity of transplanted human umbilical cord mesenchymal stem cells via HIF-1α signaling in a rat model of bronchopulmonary dysplasia.
Hao C; You J; Qiu H; Zhou O; Liu J; Zou W; Yang K; Fu Z; Zou L
Biochem Biophys Res Commun; 2022 May; 605():111-118. PubMed ID: 35316761
[TBL] [Abstract][Full Text] [Related]
15. Mussel-Inspired Nanostructures Potentiate the Immunomodulatory Properties and Angiogenesis of Mesenchymal Stem Cells.
Li T; Ma H; Ma H; Ma Z; Qiang L; Yang Z; Yang X; Zhou X; Dai K; Wang J
ACS Appl Mater Interfaces; 2019 May; 11(19):17134-17146. PubMed ID: 31008578
[TBL] [Abstract][Full Text] [Related]
16. Mesenchymal stromal cell therapy: a revolution in Regenerative Medicine?
Bernardo ME; Pagliara D; Locatelli F
Bone Marrow Transplant; 2012 Feb; 47(2):164-71. PubMed ID: 21478914
[TBL] [Abstract][Full Text] [Related]
17. Paracrine mechanisms of mesenchymal stem cell-based therapy: current status and perspectives.
Liang X; Ding Y; Zhang Y; Tse HF; Lian Q
Cell Transplant; 2014; 23(9):1045-59. PubMed ID: 23676629
[TBL] [Abstract][Full Text] [Related]
18. Conditioned media derived from mesenchymal stem cell cultures: The next generation for regenerative medicine.
Gunawardena TNA; Rahman MT; Abdullah BJJ; Abu Kasim NH
J Tissue Eng Regen Med; 2019 Apr; 13(4):569-586. PubMed ID: 30644175
[TBL] [Abstract][Full Text] [Related]
19. Enhanced cell survival and paracrine effects of mesenchymal stem cells overexpressing hepatocyte growth factor promote cardioprotection in myocardial infarction.
Zhao L; Liu X; Zhang Y; Liang X; Ding Y; Xu Y; Fang Z; Zhang F
Exp Cell Res; 2016 May; 344(1):30-39. PubMed ID: 27025401
[TBL] [Abstract][Full Text] [Related]
20. Preconditioning strategies for improving the survival rate and paracrine ability of mesenchymal stem cells in acute kidney injury.
Zhao L; Hu C; Zhang P; Jiang H; Chen J
J Cell Mol Med; 2019 Feb; 23(2):720-730. PubMed ID: 30484934
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
